Although tyrosine kinase inhibitors targeting the fibroblast growth factor receptor family are frequently associated with hyperphosphatemia, the risk of hyperphosphatemia is considered lower with bemarituzumab because it does not inhibit fibroblast growth factor 23 (FGF23) signaling, the ligand responsible for phosphate and vitamin D metabolism [100]. The gene discussed is FGF23; the disease is hyperphosphatemia.